Revenue
2021
2022
2023
2024
2025
TFA Therapeutics, Inc. (RAJAF)
Price$5.20Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $1.3M | $882,533 | $53,304 | $879,318 |
| Gross profit | $760,741 | $906,480 | $766,387 | $39,558 | −$176,212 |
| Gross margin | 61.09% | 72.32% | 86.84% | 74.21% | −20.04% |
| Research & development | — | $0 | $0 | $118,444 | $25,052 |
| Operating expenses | $901,869 | $1.1M | $538,554 | $454,679 | $119,387 |
| Operating income | −$141,128 | −$183,913 | $227,833 | −$415,121 | −$119,387 |
| Operating margin | −11.33% | −14.67% | 25.82% | −778.78% | −13.58% |
| EBITDA | −$5,885 | $223,352 | $284,590 | −$390,631 | $29,851 |
| EBITDA margin | −0.47% | 17.82% | 32.25% | −732.84% | 3.39% |
| Net income | −$154,822 | −$226,258 | $751,609 | −$720,093 | −$491,006 |
| Net profit margin | −12.43% | −18.05% | 85.16% | −1,350.92% | −55.84% |
| Basic EPSper basic share | $0.00 | $0.00 | $0.01 | -$0.01 | $0.00 |
| Diluted EPSper diluted share | $0.00 | $0.00 | $0.01 | -$0.01 | $0.00 |
Owners
Reported shareholders